Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1952 1
1963 1
1964 2
1965 1
1966 1
1967 1
1968 1
1969 2
1970 1
1971 2
1972 3
1973 3
1974 1
1975 6
1976 2
1977 2
1978 1
1979 2
1980 4
1981 1
1982 1
1983 6
1984 8
1985 10
1986 12
1987 10
1988 5
1989 17
1990 13
1991 16
1992 19
1993 16
1994 20
1995 14
1996 22
1997 21
1998 32
1999 38
2000 34
2001 36
2002 32
2003 25
2004 22
2005 21
2006 24
2007 36
2008 45
2009 46
2010 58
2011 81
2012 86
2013 92
2014 73
2015 87
2016 68
2017 58
2018 65
2019 82
2020 98
2021 105
2022 62
Text availability
Article attribute
Article type
Publication date

Search Results

1,474 results
Results by year
Filters applied: . Clear all
Page 1
Safety of biologics in psoriasis.
Kamata M, Tada Y. Kamata M, et al. Among authors: tada y. J Dermatol. 2018 Mar;45(3):279-286. doi: 10.1111/1346-8138.14096. Epub 2017 Dec 10. J Dermatol. 2018. PMID: 29226369 Review.
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.
Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, Sato E, Fukuoka S, Tada Y, Tanaka A, Morikawa H, Kawazoe A, Kinoshita T, Shitara K, Sakaguchi S, Nishikawa H. Kamada T, et al. Among authors: tada y. Proc Natl Acad Sci U S A. 2019 May 14;116(20):9999-10008. doi: 10.1073/pnas.1822001116. Epub 2019 Apr 26. Proc Natl Acad Sci U S A. 2019. PMID: 31028147 Free PMC article.
Tumor-Derived Retinoic Acid Regulates Intratumoral Monocyte Differentiation to Promote Immune Suppression.
Devalaraja S, To TKJ, Folkert IW, Natesan R, Alam MZ, Li M, Tada Y, Budagyan K, Dang MT, Zhai L, Lobel GP, Ciotti GE, Eisinger-Mathason TSK, Asangani IA, Weber K, Simon MC, Haldar M. Devalaraja S, et al. Among authors: tada y. Cell. 2020 Mar 19;180(6):1098-1114.e16. doi: 10.1016/j.cell.2020.02.042. Epub 2020 Mar 12. Cell. 2020. PMID: 32169218 Free PMC article.
Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape.
Takeuchi Y, Tanegashima T, Sato E, Irie T, Sai A, Itahashi K, Kumagai S, Tada Y, Togashi Y, Koyama S, Akbay EA, Karasaki T, Kataoka K, Funaki S, Shintani Y, Nagatomo I, Kida H, Ishii G, Miyoshi T, Aokage K, Kakimi K, Ogawa S, Okumura M, Eto M, Kumanogoh A, Tsuboi M, Nishikawa H. Takeuchi Y, et al. Among authors: tada y. Sci Immunol. 2021 Nov 12;6(65):eabc6424. doi: 10.1126/sciimmunol.abc6424. Epub 2021 Nov 12. Sci Immunol. 2021. PMID: 34767457
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
Blauvelt A, Leonardi C, Elewski B, Crowley JJ, Guenther LC, Gooderham M, Langley RG, Vender R, Pinter A, Griffiths CEM, Tada Y, Elmaraghy H, Lima RG, Gallo G, Renda L, Burge R, Park SY, Zhu B, Papp K; IXORA-R Study Group. Blauvelt A, et al. Among authors: tada y. Br J Dermatol. 2021 Jun;184(6):1047-1058. doi: 10.1111/bjd.19509. Epub 2020 Oct 25. Br J Dermatol. 2021. PMID: 32880909 Free PMC article. Clinical Trial.
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J; IXORA-R Study Group. Blauvelt A, et al. Among authors: tada y. Br J Dermatol. 2020 Jun;182(6):1348-1358. doi: 10.1111/bjd.18851. Epub 2020 Jan 15. Br J Dermatol. 2020. PMID: 31887225 Free PMC article. Clinical Trial.
1,474 results